Journal rankings · indicator year 2004
Choose a field to open its ranking, or a journal to find its row in its subfield’s list.
Field ranking · 2004
Pharmacology, Toxicology and Pharmaceutics journal rankings 2004
32 ranked journals · Field in Life Sciences
Pharmacology, Toxicology and Pharmaceutics has 32 ranked journals in 2004. The median journal has an OJR of 0.86, below the world average of 1.00, down 0.01 on 2003; Q1 starts at OJR 1.38. The top three are Pharmacogenetics, Current Drug Metabolism, and Drug Safety.
Ranks and citation indicators: 2004. Journal access status and listed APC: source snapshot September 23, 2026.
Journals whose main subfield sits in this category and that published at least 30 citable documents (articles, reviews and conference papers) in 2001–2003, the window the 2004 score is computed on.
The OpenJournalRank Indicator (OJR) is a free, publicly available metric of a journal’s field-normalized citation impact, computed from open OpenAlex citation data. It compares citations to a journal’s papers from the previous three years with the world average for papers of the same subfield, year and type, so 1.00 is the world average and values can be compared across fields. It is computed with the NCI3 method.
The middle OJR among ranked journals in this category: half score higher, half lower. 1.00 is the world average for papers of the same subfield, year and type.
The dot is this category, the solid tick is the median of all ranked journals and the dashed line is the world average.
Share of ranked journals in this category that are fully open access, so every paper is free to read. Hybrid journals, which sell subscriptions and open single papers for a fee, are not counted.
Median list price of the article processing charge, in US dollars, among ranked journals in this category that list a price above zero. Journals with a listed APC of $0 and journals with no known price are left out of this median. The At a glance table below gives a second median that includes the $0 prices.
Subfields in Pharmacology, Toxicology and Pharmaceutics (4)
Up to Life Sciences32 ranked journals
Filters
Rank is the position by OJR within the list on screen; 1 is the highest. | OJR is field-normalized 3-year citation impact: 1.00 is the world average for papers of the same subfield, year and type, so values compare across fields. The badge is the journal’s quartile in this list. | Citations per paper over a two-year window, counted from OpenAlex. It is not field-normalized, so compare it only between journals of the same field. ▲ or ▼ is the change from 2003. This is OpenJournalRank’s own count, not Clarivate’s Journal Impact Factor. | Citable documents (articles, reviews and conference papers) published in 2001–2003, the window the 2004 OJR is computed on. A journal needs at least 30 to be ranked. | Share of the journal’s 2001–2003 papers that are free to read in any open-access form. The green OA tag next to a title marks a fully open-access journal. | List price of the article processing charge in US dollars. “$0 listed” means the listed price is zero; a dash means no price is listed. | The line is the journal’s OJR from 2000 to 2004. | Compare |
|---|---|---|---|---|---|---|---|
1PharmacogeneticsLippincott Williams & Wilkins · United Kingdom | 3.02Q1 | 6.20 0.15 up from 2003 | 299 | 5% | — | ||
2Current Drug MetabolismBentham Science Publishers · Netherlands | 2.54Q1 | 4.53 0.39 up from 2003 | 106 | 0% | — | ||
3Drug SafetyAdis, Springer Healthcare · New Zealand | 2.21Q1 | 4.02 0.06 down from 2003 | 266 | 4% | $4,990 | ||
4Critical Reviews in Therapeutic Drug Carrier SystemsBegell House · United States | 2.16Q1 | 3.78 0.33 down from 2003 | 42 | 0% | — | ||
5Drug Metabolism and DispositionAmerican Society for Pharmacology and Experimental Therapeutics · United States | 2.10Q1 | 4.37 0.90 up from 2003 | 441 | 3% | $3,500 | ||
6The Pharmacogenomics JournalSpringer Nature · United Kingdom | 1.71Q1 | 3.88 1.00 up from 2003 | 190 | 9% | $4,890 | ||
7PharmacogenomicsFuture Medicine · United Kingdom | 1.46Q1 | 3.22 0.61 up from 2003 | 205 | 1% | — | ||
8Pharmaceutical ResearchSpringer Science+Business Media · United States | 1.38Q1 | 2.75 0.10 up from 2003 | 840 | 7% | $4,690 | ||
9International Journal of PharmaceuticsElsevier BV · Netherlands | 1.36Q2 | 2.09 0.26 up from 2003 | 1,399 | 3% | $4,650 | ||
10European Journal of Pharmaceutics and BiopharmaceuticsElsevier BV · Netherlands | 1.34Q2 | 2.00 0.41 up from 2003 | 349 | 9% | $4,210 | ||
11Journal of MicroencapsulationTaylor & Francis · United Kingdom | 1.11Q2 | 1.60 0.24 up from 2003 | 257 | 4% | — | ||
12European Journal of Pharmaceutical SciencesOAElsevier BV · Netherlands | 1.11Q2 | 1.78 0.14 down from 2003 | 519 | 4% | $3,070 | ||
13XenobioticaTaylor & Francis · United Kingdom | 1.10Q2 | 1.92 0.22 down from 2003 | 243 | 4% | — | ||
14Journal of Analytical ToxicologyOxford University Press · United Kingdom | 1.03Q2 | 1.98 0.04 down from 2003 | 310 | 36% | $4,823 | ||
15AAPS PharmSciAmerican Association of Pharmaceutical Scientists · United States | 0.94Q2 | 1.66 0.26 up from 2003 | 119 | 94% | — | ||
16Journal of Fluorine ChemistryElsevier BV · Netherlands | 0.86Q2 | 1.28 0.11 up from 2003 | 696 | 3% | $3,660 | ||
17Expert Opinion on Drug SafetyTaylor & Francis · United Kingdom | 0.86Q3 | 1.59 1.06 up from 2003 | 82 | 7% | — | ||
18Drug Development and Industrial PharmacyTaylor & Francis · United States | 0.79Q3 | 1.15 0.21 up from 2003 | 368 | 4% | — | ||
19Biopharmaceutics & Drug DispositionWiley · United Kingdom | 0.79Q3 | 1.27 0.55 down from 2003 | 123 | 6% | $3,800 | ||
20Drug metabolism and drug interactionsDe Gruyter · Germany | 0.67Q3 | 1.21 0.29 up from 2003 | 35 | 4% | — | ||
21Drug DeliveryOATaylor & Francis · United Kingdom | 0.63Q3 | 0.96 0.19 down from 2003 | 112 | 97% | $2,864 | ||
22Pharmaceutical Development and TechnologyTaylor & Francis · United States | 0.61Q3 | 0.79 0.14 down from 2003 | 151 | 2% | — | ||
23Drug Metabolism and PharmacokineticsElsevier BV · Japan | 0.49Q3 | 1.09 0.39 up from 2003 | 117 | 2% | $3,580 | ||
24AAPS PharmSciTechSpringer Science+Business Media · United States | 0.39Q3 | 1.15 0.54 up from 2003 | 167 | 74% | $4,190 | ||
25Assay and Drug Development TechnologiesMary Ann Liebert, Inc. · United States | 0.38Q4 | 1.13 0.59 down from 2003 | 103 | 0% | — | ||
26European Journal of Drug Metabolism and PharmacokineticsAdis, Springer Healthcare · France | 0.28Q4 | 0.45 0.01 down from 2003 | 139 | 0% | $2,690 | ||
27Dissolution TechnologiesUnited States | 0.24Q4 | 0.37 0.06 up from 2003 | 46 | 83% | — | ||
28YAKUGAKU ZASSHIOAPharmaceutical Society of Japan · Japan | 0.21Q4 | 0.40 0.12 down from 2003 | 331 | 84% | — | ||
29Annales de Toxicologie AnalytiqueElsevier BV · France | 0.19Q4 | 0.36 0.17 up from 2003 | 101 | 100% | $3,140 | ||
30Journal of Pharmaceutical Marketing & ManagementHaworth Press · United States | 0.16Q4 | 0.11 0.06 up from 2003 | 98 | 0% | — | ||
31Scientia PharmaceuticaOAÖsterreichische Apotheker-Verlagsgesellschaft m. b. H. · Switzerland | 0.11Q4 | 0.16 0.01 up from 2003 | 104 | 100% | $1,207 | ||
32Journal of Pharmaceutical InvestigationSpringer Science+Business Media · South Korea | 0.02Q4 | 0.00no change | 40 | 7% | $3,890 |
Subfields of Pharmacology, Toxicology and Pharmaceutics, compared.
Journals
Citations made in 2004. Corpus-wide, 69.4% of core-journal articles and reviews published that year have at least one matched reference; the share varies by journal and field.
9 additional Pharmacology, Toxicology and Pharmaceutics journals with metrics are unranked under this release’s eligibility rules: a journal needs at least 30 citable documents in 2001–2003, at least 80% of them with a subfield, and a positive world-average expectation. Ranks are within the whole category; filters hide rows without re-ranking. OJR excludes self-citations.
At a glance
Indicator year: 2004. Publication window: 2001–2003. How these summaries are calculated
- Ranked journals
- 32
- Window papers (baseline)
- 26,889 +23.8% from indicator year 2001
- Median OJR
- 0.86 +20.2% from indicator year 2001
- Rising journals (2025)
- 4Comparison-group list (4)
Window papers are the baseline paper population: citable papers (articles, reviews and conference papers) from 2001–2003 in all journals of the world-average baseline, including non-core journals, counted by each paper’s own subfield. They are not the papers of the ranked journals alone.
| Measure | Year series | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ranked journals | 23 | 27 | 30 | 32 | 32 | 34 | 37 | 38 | 40 | 43 | 44 | 49 | 54 | 61 | 69 | 71 | 74 | 71 | 73 | 75 | 70 | 72 | 75 | 73 | 72 | 68 | |
| Window papers (baseline) | 20,428 | 21,714 | 23,158 | 25,397 | 26,889 | 29,157 | 31,606 | 34,777 | 38,146 | 41,640 | 45,814 | 49,553 | 53,613 | 56,245 | 59,173 | 59,681 | 59,061 | 56,321 | 53,536 | 51,719 | 51,606 | 54,267 | 56,608 | 57,539 | 56,944 | 58,541 | |
| Median OJR | 0.620 | 0.717 | 0.722 | 0.88 | 0.86 | 0.83 | 0.91 | 1.11 | 0.9471 | 0.97 | 0.949 | 1.03 | 0.9469 | 0.80 | 0.70 | 0.720 | 0.61 | 0.7184 | 0.74 | 0.628 | 0.77 | 0.621 | 0.67 | 0.630 | 0.625 | 0.7176 |
| Measure | Category statistic | Eligible population |
|---|---|---|
| Journal self-citation share | Median: 2.7% | 62 journals |
| Retracted papers per 1,000 | Pooled rate: 1.221 per 1,000 | 51 journals |
| Output growth | Median: -1.6% | 60 journals |
| Open access share | Median: 44.5% | 68 journals |
| Listed APC (USD) | Median including $0 listed prices: $3,605 | 32 ranked journals with a known listed price, including $0 listed prices |
| International collaboration share | Median: 22.2% | 67 journals |
| Review share | Median: 0.4% | 68 journals |
| Articles-only OJR | Median: 0.74 | 68 journals |
| Uncited share | Median: 25.2% | 68 journals |
| Citation concentration | Median: 43.7% | 68 journals |
How to read these rankings
- OJR, the OpenJournalRank Indicator
- A field-normalized 3-year citation impact, computed from OpenAlex with the NCI3 method. It divides the citations a journal’s papers received by the world average for papers of the same subfield, year and type, so 1.00 is the world average and 2.00 means twice as many citations as expected. Because it is normalized, it can be compared across fields. Read the methodology
- Quartiles
- Q1 to Q4 split the ranked journals of the list you are viewing into four equal groups by OJR. A journal’s quartile depends on the list: the same journal can be Q1 in its subfield and Q2 among all journals.
- Impact factor (2-year)
- Citations per paper over a two-year window, counted from OpenAlex. It is easy to compare with familiar impact factors but is not field-normalized, so compare it only within a field. It is not Clarivate’s Journal Impact Factor. Why it differs from the Journal Impact Factor
- Rank ranges
- Each rank in the latest year carries a likely range from 1,000 resamples of the journal’s papers. Where two journals’ ranges overlap, the data cannot tell them apart, so treat neighbouring ranks as ties.